Trial Profile
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2019
Price :
$35
*
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Tris Pharma
- 14 Jun 2019 Status changed from active, no longer recruiting to completed.
- 01 Feb 2019 Primary endpoint (Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores Baseline to 30 Minutes Post Dose) has been met, according to Journal of Child and Adolescent Psychopharmacology.
- 12 Nov 2018 Results presented in the Tris Pharma media release.